3-(phenylamino)isonicotinic acid | 64021-70-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(phenylamino)isonicotinic acid
• 英文别名: 3-Phenylaminopyridin-4-carbonsaeure；4-Carboxy-3-anilino-pyridin；3-anilino-isonicotinic acid；3-Anilino-isonicotinsaeure；3-Anilinopyridine-4-carboxylic acid
• CAS: 64021-70-1
• 化学式: C₁₂H₁₀N₂O₂
• 分子量: 214.224
• InChiKey: XPPXHAOZWPYYAJ-UHFFFAOYSA-N

物化性质

• 熔点：
  304-305 °C(Solv: N,N-dimethylformamide (68-12-2))
• 沸点：
  478.0±30.0 °C(Predicted)
• 密度：
  1.328±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(phenylamino)isonicotinic acid 在 正丁基锂 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 4.5h， 生成 ethyl 3-(3-anilino-4-pyridinyl)-3-oxopropanoate
  参考文献：
  名称：

  [EN] COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF DIABETES AND DIABETES-RELATED DISORDERS
  [FR] COMPOSES ET COMPOSITIONS DE TRAITEMENT DU DIABETE ET DES TROUBLES ASSOCIES AU DIABETE

  摘要：

  公开号：

  WO2003101988A3
• 作为产物：
  描述：

  3-溴异烟酸甲酯 在 tris-(dibenzylideneacetone)dipalladium(0) 、 lithium hydroxide monohydrate 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 17.0h， 生成 3-(phenylamino)isonicotinic acid
  参考文献：
  名称：

  INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN

  摘要：

  描述了用于调节成纤维细胞活化蛋白（FAP）的化合物和组合物。这些化合物和组合物可能被用作治疗疾病的治疗剂，包括高增殖性疾病。

  公开号：

  US20190185451A1

文献信息

• Compounds and compositions for the treatment of diabetes and diabetes-related disorders
  申请人：Wang Yamin

  公开号：US20060009483A1

  公开（公告）日：2006-01-12

  The present invention relates to novel compounds which are useful in the treatment of diabetes and diabetes-related disorders. The invention also relates to pharmaceutical compositions comprising said compounds, intermediates useful in the preparation of said compounds, and methods of preparation.

  本发明涉及一种新型化合物，其在治疗糖尿病和糖尿病相关疾病方面具有用途。该发明还涉及包含所述化合物的药物组合物、制备所述化合物的中间体以及制备方法。
• Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors
  申请人：Goutopoulos Andreas

  公开号：US20070287737A1

  公开（公告）日：2007-12-13

  The invention provides novel heteroaryl-substituted arylaminopyridine derivative MEK inhibitors of Formula (Ia) Such compounds are MEK inhibitors that are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation. Also disclosed is the treatment of a hyperproliferative disease in mammals, and pharmaceutical compositions containing such compounds.

  该发明提供了新型杂环取代的芳胺基吡啶衍生物MEK抑制剂，其化学式为(Ia)。这些化合物是MEK抑制剂，可用于治疗高增殖性疾病，如癌症和炎症。还披露了在哺乳动物中治疗高增殖性疾病的方法，以及含有这些化合物的药物组合物。
• 3-Arylamino pyridine derivatives
  申请人：Abel Ulricn

  公开号：US20090093462A1

  公开（公告）日：2009-04-09

  The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

  本发明提供了新型的取代的3-芳基氨基吡啶化合物(I)，其药学上可接受的盐、溶剂和前药化合物，其中W、R1、R2、R9、R10、R11、R12、R13、R14如规范中所定义。这些化合物是MEK抑制剂，可用于治疗高增殖性疾病，如癌症、再狭窄和炎症。本发明还揭示了在哺乳动物，特别是人类中治疗高增殖性疾病的这些化合物的用途，以及包含这些化合物的制药组合物。
• 3-Arylamino Pyridine Derivatives
  申请人：Abel Ulrich

  公开号：US20110224192A1

  公开（公告）日：2011-09-15

  The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

  该发明提供了新型的取代的3-芳基氨基吡啶化合物及其药学上可接受的盐、溶剂化物和前药化合物，其中W、R1、R2、R9、R10、R11、R12、R13、R14在说明书中有定义。这些化合物是MEK抑制剂，可用于治疗过度增殖性疾病，如癌症、再狭窄和炎症。还公开了在哺乳动物，特别是人类中治疗过度增殖性疾病的使用以及含有这些化合物的制药组合物。
• Antiallergy agents. 1. Substituted 1,8-naphthyridin-2(1H)-ones as inhibitors of SRS-A release
  作者：Margaret H. Sherlock、James J. Kaminski、Wing C. Tom、Joe F. Lee、Shing Chun Wong、William Kreutner、Robert W. Bryant、Andrew T. McPhail

  DOI：10.1021/jm00119a010

  日期：1988.11

  A novel class of antiallergy agents, the substituted 1,8-naphthyridin-2(1H)-ones, is described. The present compounds are orally active, potent inhibitors of allergic and nonallergic bronchospasm in animal models. Structure-activity studies of the lead compound in this series, 1-phenyl-3-n-butyl-4-hydroxynaphthyridin-2(1H)-one (11), identified three compounds of interest, 1-phenyl-3-(2-propenyl)-4-acetoxy-1,8-naphthyridin-2(1H)-one (12), 1-(3'-chlorophenyl)-3-(2-propenyl)-4-acetoxy-1,8-naphthyridin-2(1H )-one (87), and 1-(3'-methoxyphenyl)-3-(2-propenyl)-4-acetoxy-1,8-naphthyridin-2(1 H)-one (89). The mechanism of antiallergy activity may involve inhibition of the release of the sulfidopeptide leukotrienes. 1-Phenyl-3-(2-propenyl)-4-acetoxy-1,8-naphthyridin-2(1H)-one, Sch 33303 (12), was selected for preclinical development as an antiallergy agent.